Tag Archives: Sinovac

Sinovac vaccine recipients more likely to develop severe COVID-19 than Pfizer: Study – CNA

  1. Sinovac vaccine recipients more likely to develop severe COVID-19 than Pfizer: Study CNA
  2. Singapore study shows people who got Sinovac jabs are 5 times at risk of severe COVID symptoms than with Pfizer jabs The Independent
  3. S’pore Study Shows Which COVID-19 Vaccine Can Better Prevent Severe Symptoms Goody Feed
  4. People who got Sinovac vaccine nearly 5 times more likely to develop severe COVID-19 than Pfizer: Singapore study CNA
  5. Severe Covid-19 symptoms 5 times more likely in those who got Sinovac rather than Pfizer jab, study shows AsiaOne
  6. View Full Coverage on Google News

Read original article here

Sinovac COVID-19 shot with Pfizer booster less effective against Omicron – study

The Sinovac vaccine is pictured at StarMed Specialist Centre, a private medical centre, in Singapore July 13, 2021. REUTERS/Caroline Chia

Register now for FREE unlimited access to Reuters.com

Register

Dec 31 (Reuters) – Sinovac’s two-dose COVID-19 vaccine followed by a booster Pfizer-BioNTech shot showed a lower immune response against the Omicron variant compared with other strains, according to a study by researchers.

The study, which has not been peer-reviewed yet, was conducted by researchers from Yale University, the Dominican Republic’s Ministry of Health and other institutions.

The Sinovac (SVA.O) two-dose regimen along with the Pfizer (PFE.N) shot produced an antibody response similar to a two-dose mRNA vaccine, according to the study. Antibody levels against Omicron were 6.3-fold lower when compared with the ancestral variant and 2.7-fold lower when compared with Delta.

Register now for FREE unlimited access to Reuters.com

Register

Akiko Iwasaki, one of the authors of the study, said on Twitter that CoronaVac recipients may need two additional booster doses to achieve protective levels needed against Omicron.

The two-dose Sinovac vaccine alone did not show any detectable neutralization against Omicron, according to the study that analysed plasma samples from 101 participants in the Dominican Republic.

A study from Hong Kong last week said that even three doses of the Sinovac vaccine did not produce enough antibody response against Omicron and that it had to be boosted by a Pfizer-BioNTech shot to achieve “protective levels.” read more

Sinovac’s CoronaVac and state-owned Sinopharm’s BBIBP-CorV vaccine are the two most-used vaccines in China and the leading COVID-19 shots exported by the country. Hong Kong has been using the Sinovac and Pfizer-BioNTech vaccines.

Register now for FREE unlimited access to Reuters.com

Register

Reporting by Jose Joseph and Shubham Kalia in Bengaluru; Editing by Ramakrishnan M.

Our Standards: The Thomson Reuters Trust Principles.



Read original article here

Brazil health regulator suspends use of 12 mln Sinovac vaccine shots

An employee handles vials containing CoronaVac, Sinovac Biotech’s vaccine against the coronavirus disease (COVID-19), at Butantan biomedical center in Sao Paulo, Brazil January 12, 2021. REUTERS/Amanda Perobelli

SAO PAULO, Sept 4 (Reuters) – Brazil’s federal health regulator Anvisa on Saturday suspended the use of over 12 million doses of a COVID-19 vaccine developed by China’s Sinovac Biotech Ltd (SVA.O) that were produced in an unauthorized plant, it said in a statement.

Anvisa said it was alerted on Friday by Sao Paulo’s Butantan institute, a biomedical center that has partnered with Sinovac to locally fill and finish the vaccines, that 25 batches, or 12.1 million doses, sent to Brazil had been made in the plant.

“The manufacturing unit … was not inspected and was not approved by Anvisa in the authorization of emergency use of the mentioned vaccine,” the regulator said. The ban was “a precautionary measure to avoid exposing the population to possible imminent risk,” it added.

Butantan also told Anvisa that another 17 batches, totaling 9 million doses, had been produced in the same plant, and were on their way to Brazil, the regulator said.

During the 90-day ban, Anvisa will seek to inspect the plant, and find out more about the security of the manufacturing process, it said.

During Brazil’s vaccine rollout earlier this year, the vast majority of administered vaccines were from Sinovac. More shots from other manufacturers have since come online.

Brazil on Saturday reported 21,804 new coronavirus cases, and 692 COVID-19 deaths.

Reporting by Gabriel Stargardter; Editing by Richard Chang

Our Standards: The Thomson Reuters Trust Principles.

Read original article here

Thailand plans to mix Sinovac and AstraZeneca Covid-19 vaccines. Critics say that’s risky

There has been no research released specifically about mixing the two types, but a growing number of countries are looking at mix-and-match approaches to better protect from highly transmissible variants — with Vietnam the latest.

At a health ministry news conference, Yong Poovorawan, a virology expert at Chulalongkorn University, said 1,200 people in Thailand had already received the Sinovac-AstraZeneca combination — in different orders — mainly due to allergic reactions to their first doses, requiring them to change vaccine.

“There were no severe side effects, which indicates that it is safe for real usage,” Yong said.

Yong said a preliminary result from his study on 40 subjects showed a shot of the inactivated vaccine of China’s Sinovac followed by one of the viral vector vaccine of AstraZeneca resulted in a similar buildup of antibodies to recipients of two doses of the AstraZeneca shot.

Thailand announced on Monday that combination would be adopted.

But some critics called that risky.

“Thai people are not test subjects,” said Rewat Wisutwet, a doctor and lawmaker from the Seri Ruam Thai Party.

In Nonthaburi, a province bordering Bangkok, an offer on Facebook by health authorities for 20,000 people to receive the Sinovac-AstraZeneca mix drew close to 700 mostly critical comments.

“I am not a lab mouse,” said one post, while another said: “This is like playing with peoples’ lives.”

Another wrote: “If the first dose is Sinovac, then please cancel it.”

Sinovac did not respond to Reuters’ request for comment on the Thai plan Monday and AstraZeneca said vaccine policy was for each country to decide.

Thai health authorities said Monday that health care workers would receive a booster shot of either AstraZeneca or Pfizer, after 618 of more than 677,000 medical personnel who received two doses of Sinovac tested positive for Covid-19. Of the 618 who tested positive, only two became seriously ill, including one nurse who died.

“Despite that, all vaccines have been proven to be efficient in preventing hospitalization and death,” Ministry of Foreign Affairs official Pensom Lertsithichai said at a briefing Monday, adding that medical workers had high exposure to Covid-19 which could have contributed to “vaccination failure.”

Thailand is suffering its worst coronavirus outbreak yet and authorities on Tuesday approved use of home rapid antigen self-test kits, as the capital Bangkok’s health care and testing facilities come under strain.

It has also given the go-ahead for home or community isolation for asymptomatic or mildly symptomatic cases.

Thailand recorded 8,685 infections and 56 deaths on Tuesday, among the 353,712 cases and 2,847 fatalities overall — most of those recorded in the past three months.

CNN’s Julia Hollingsworth contributed reporting.

Read original article here

Lead Sinovac vaccine scientist in Indonesia dies of suspected COVID-19, media say

The death of Novilia Sjafri Bachtiar comes as fatalities from the coronavirus reach record highs in Indonesia, one of the countries where the Sinovac vaccine has been most widely used.

Kumparan news service said Novilia had died of the coronavirus. Sindonews quoted an official of state-owned pharmaceuticals company BioFarma as saying she had been buried according to Covid-19 protocols.

State enterprises minister Erick Thohir posted a message on Instagram mourning her “huge loss” at BioFarma, which is making the vaccine. He did not give the cause of her death.

“She was lead scientist and head of dozens of clinical trials done by BioFarma, including Covid-19 vaccine clinical trials in cooperation with Sinovac,” he said.

“It has been produced and injected into tens of millions people in Indonesia, as part of our effort to be free from this Covid-19 pandemic.”

BioFarma did not immediately respond to a request for comment on the death of Novilia, who was in her early fifties.

The infection and deaths of health workers in Indonesia who had received the Sinovac vaccine has added to questions over its effectiveness in preventing hospitalization and death.

According to independent data group Lapor Covid-19, 131 healthcare workers, mostly vaccinated with the Sinovac shot, have died since June, including 50 in July.

Indonesia reported more than 1,000 coronavirus deaths in a day for the first time on Wednesday and a record 34,379 infections. The latest wave of infections has been driven by the Delta variant, first identified in India.

Last month, Sinovac spokesman Liu Peicheng told Reuters preliminary results showed the vaccine produced a three-fold reduction in neutralizing effect against the Delta variant.

Read original article here

Singapore not counting Sinovac shots in COVID-19 vaccination tally

People queue to enquire about Sinovac vaccine at a clinic, during the coronavirus disease (COVID-19) outbreak in Singapore June 18, 2021. REUTERS/Chen Lin

SINGAPORE, July 7 (Reuters) – Singapore has excluded those who received Sinovac Biotech’s (SVA.O) shots from its national COVID-19 vaccination count, according to the city-state’s health ministry.

“The national vaccination numbers reflect only those vaccinated under the national vaccination programme,” the ministry said in an emailed statement on Wednesday.

Currently, this only includes those vaccinated with the Moderna Inc (MRNA.O) and Pfizer-BioNTech/Cominarty (PFE.N), vaccines, it said.

Sinovac’s CoronaVac shot is not part of Singapore’s national vaccination programme and the city-state has said it is still awaiting critical data from the company.

It has, however, allowed the usage of the vaccine by private healthcare institutions under a special access route, following an emergency use approval by the World Health Organization (WHO). Selected private clinics can draw on the country’s current stock of 200,000 CoronaVac doses. read more

About 3.7 million people have received at least one dose of the Pfizer or Moderna’s vaccines, covering about 65% of the population, and nearly 2.2 million have completed the regimen.

Singapore has set a target for two-thirds of its people to complete the two-dose regimen by around Aug. 9.

Both have shown efficacy rates of well over 90% against symptomatic disease in clinical trials, compared with trials for Sinovac that shown results from as low as 51% to about 84%. Sinovac did not respond to a request for comment on its efficacy rates earlier this week.

Kenneth Mak, Singapore’s director of medical services, said last month evidence from other countries showed people who had taken the Sinovac vaccine were still getting infected.

“There is a significant risk of vaccine breakthrough,” he said.

Just over 17,000 people in Singapore have received one dose of CoronaVac as of July 3. These records will be captured in a national immunisation registry.

Recipients of the Sinovac vaccine are also not exempt from COVID-19 tests required before attending certain events or entering some venues. Those who have completed the full vaccination regimen with Moderna or Pfizer are exempt from such pre-event testing.

“COVID-19 vaccines that are not part of our national vaccination programme may not have documented sufficient data on their protection against COVID-19 infection, especially against the Delta variant that is currently circulating,” the health ministry said last week.

Reporting by Aradhana Aravindan in Singapore
Editing by Ed Davies

Our Standards: The Thomson Reuters Trust Principles.

Read original article here

Sinovac vaccine may not trigger sufficient antibody response to Brazil variant: study

Refinery29

No, Johnson & Johnson’s Vaccine Isn’t “Less Effective” — Here’s Why

A vial of the Johnson & Johnson Janssen Covid-19 vaccine at Northwell Health South Shore University Hospital in Bay Shore, New York, U.S., on Wednesday, March 3, 2021. President Biden said that Merck & Co. will help make Johnson & Johnson’s single-shot coronavirus vaccine, a collaboration between rivals aimed at ramping up the pace of inoculations that will help provide enough supply for every adult in the U.S. by the end of May. Photographer: Johnny Milano/Bloomberg via Getty Images Nationwide, people are grappling with the weight of life during the coronavirus pandemic as they reflect on an entire year living under some kind of lockdown. For many, the pandemic has meant working from home, less physical contact with family and friends, and a complete change in how they interact with everyday life in an effort to keep themselves and their loved ones safer from the deadly virus. But there is some hope for relief, now that a third vaccine has been approved by the Food and Drug Administration (FDA) for emergency use. Johnson & Johnson’s single-dose COVID-19 vaccine is now being administered across the country for people ages 18 and older. Despite the fact that there are now even more vaccines being made available to millions of people across the country, some are skeptical that the J&J vaccine is less effective than the Moderna and Pfizer two-dose vaccines, due to lower efficacy numbers. Media reports on the new vaccine have focused their attention on its efficacy rate: 72% for Johnson & Johnson, compared to 94% for Moderna and 95% for Pfizer. But the lower rate shouldn’t discourage anyone from getting the single-dose vaccine, which is equally as effective as the other two at preventing serious illness, according to The New York Times. The J&J vaccine’s lower effectiveness number refers only to its ability to prevent all infections as a result of contracting the SARS-Cov-2 virus. While it may not be as good at preventing mild COVID cases, Johnson & Johnson’s single dose is just as successful as the other two at preventing the most serious cases of this virus, and that’s most important. For more context, the Johnson & Johnson vaccine is also more effective than the flu shot. According to the Centers for Disease Control and Prevention (CDC), “flu vaccination reduces the risk of flu illness by between 40% and 60% among the overall population during seasons when most circulating flu viruses are well-matched to the flu vaccine.” Dr. Robert Wachter, chair of the department of medicine at the University of California, San Francisco told The New York Times that with any of the three vaccines, “There’s essentially no chance you will die of COVID, which is breathtaking.” This is notable, considering the virus has killed more than half a million people in the U.S. over the last year. The goal of any of the three vaccines is not to completely root out COVID-19, which is likely here to stay. Instead, the hope is to turn the virus into something like a mild flu or the common cold while we seek to achieve herd immunity and in that regard, things are looking up. “When you think of what do you want from a vaccine, you don’t want to go to the hospital, and you certainly don’t want to die,” Johnson & Johnson CEO and Chairman Alex Gorsky told CNBC’s Squawk Box. “And what we have seen as far as 100% efficacy in those parameters, again with a single shot.” Experts say they would recommend any of the three vaccines and suggest that people get whichever one is first made available to them. That is our best possible tool when it comes to moving past the pandemic. Lisa Lee, an infectious disease epidemiologist and public health ethicist at Virginia Tech, said last month that a third vaccine option “substantially reduces the time it takes the U.S. to reach herd immunity.” Lee also noted that as more of the population becomes vaccinated, there is less opportunity for further mutations of the virus to develop. “When we stop transmitting between people, we also stop the opportunity for mutation,” she told CNBC. After a long year in relative isolation, as people sit with the grief of losing their old ways of living and their loved ones and the uncertainty of what comes next, it’s only natural that they might question the efficacy of a new vaccine. We’ve been dealt so many blows in the last year, after all. But rest assured that if your time comes for the vaccine and the Johnson & Johnson single-dose shot is made available to you, it’s just one more layer of protection for all of us. Like what you see? How about some more R29 goodness, right here?I Helped Create The Johnson & Johnson VaccineWill Everyone Be Able To Get Vaccinated By May?Inside The Fierce Hunt For Leftover Vaccines

Read original article here